Advanced Squamous Non-small Cell Lung Research Articles

PCN117 - Resource Utilization Among Advanced Squamous and non-Squamous non-Small Cell Lung Cancer Patients Receiving Second-Line Treatment in France, Germany, Italy, and Spain: Results of A Retrospective Medical Chart Review

PCN117 - Resource Utilization Among Advanced Squamous and non-Squamous non-Small Cell Lung Cancer Patients Receiving Second-Line Treatment in France, Germany, Italy, and Spain: Results of A Retrospective Medical Chart Review

Clinical Analysis of Efficacy of Albumin Bound Paclitaxel Plus Platinum Compounds and Gemcitabine Plus Platinum Compounds as First-Line Chemotherapy for Advanced Squamous Non-Small Cell Lung Cancer

Clinical Analysis of Efficacy of Albumin Bound Paclitaxel Plus Platinum Compounds and Gemcitabine Plus Platinum Compounds as First-Line Chemotherapy for Advanced Squamous Non-Small Cell Lung Cancer

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.

The treatment of cancer has largely relied on killing tumor cells with nonspecific cytotoxic therapies and radiotherapy. This approach, however, has limitations including severe systemic toxicities, bystander effects on normal cells, recurrence of drug-resistant tumor cells, and the inability to target micrometastases or subclinical disease. An increased understanding of the critical role of the immune system in cancer development and progression has led to new treatment strategies using various immunotherapies. It is now recognized that established tumors have numerous mechanisms of suppressing the antitumor immune response including production of inhibitory cytokines, recruitment of immunosuppressive immune cells, and upregulation of coinhibitory receptors known as immune checkpoints. This review focuses on the immune checkpoint inhibitors, a novel class of immunotherapy first approved in 2011. Our objective is to highlight similarities and differences among the three immune checkpoint inhibitors approved by the U.S. Food and Drug Administration-ipilimumab, pembrolizumab, and nivolumab-to facilitate therapeutic decision making. We conducted a review of the published literature and conference proceedings and present a critical appraisal of the clinical evidence supporting their use in the treatment of metastatic melanoma and advanced squamous non-small cell lung cancer (NSCLC). We also compare and contrast their current place in cancer therapy and patterns of immune-related toxicities, and discuss the role of dual immune checkpoint inhibition and strategies for the management of immune-related adverse events. The immune checkpoint inhibitors have demonstrated a dramatic improvement in overall survival in patients with advanced melanoma and squamous NSCLC, along with acceptable toxicity profiles. These agents have a clear role in the first-line treatment of advanced melanoma and in the second-line treatment of advanced squamous NSCLC.

3112 Nintedanib in combination with cisplatin/gemcitabine as 1st-line therapy for advanced squamous non-small cell lung cancer

3112 Nintedanib in combination with cisplatin/gemcitabine as 1st-line therapy for advanced squamous non-small cell lung cancer

3011 Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017

3011 Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017

521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

The importance of response to chemotherapy in advanced squamous non-small cell lung cancer (NSCLC).

e17694 Background: A phase III clinical trial demonstrated that nab-paclitaxel plus carboplatin significantly improved objective overall response rate compared with solvent-based paclitaxel plus ca...

Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).

8027 Background: Nivolumab, a fully human IgG4, PD-1 immune-checkpoint inhibitor antibody, has shown durable clinical activity in phase I and II trials in several tumor types. Recently, a phase III...

Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial.

8049 Background: Docetaxel (D) or Erlotinib (E) are registered second-line treatments for EGFR wild type NSCLC. Previous studies suggested a predictive value of the serum proteomic VeriStrat test (VS), assigning a good (VSG) or poor (VSP) classification in second-line therapy of patients (pts.) with NSCLC. EMPHASIS aimed at exploring a predictive interaction in SqNSCLC pts. The trial closed prematurely due to low accrual. Methods: EMPHASIS is a randomized phase III multicenter trial exploring the differential activity of second line E vs D on progression-free survival (PFS) in VSG vs VSP SqNSCLC. The expected hazard ratio (HR) of E vs D was 0.675 for the VSG patients (median PFS, E: 4.0 and D: 2.7 mo.), and 1.23 for the VSP patients (median PFS, E: 2.2 and D: 2.7 mo.). A sample size of 500 was needed to achieve 86% power for testing the expected interaction HR of 1.82 at a two-sided p-value of 0.05. Pts were randomized to receive treatment E150 mg p.o. daily or D 75 mg/m2 i.v. on day 1 of each 21 day cycl...

A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).

8009 Background: Treatment options are limited for patients (pts) with advanced SQ NSCLC who fail platinum-based doublet chemotherapy (PT-DC). We report results of a randomized, open-label, global ...

Real-world treatment patterns for advanced squamous non-small cell lung cancer in the U.S. Medicare population.

e17652 Background: Advanced squamous non-small cell lung cancer (NSCLC) represents approximately 22% of all lung cancer cases in the US. Although prognosis is generally poor, treatment selection pl...

CP-102 Carboplatin – paclitaxel – bevacizumab based treatment for non-small cell lung advanced cancer patients: use review

BackgroundBevacizumab added to carboplatin and paclitaxel is indicated for first-line treatment in advanced non squamous non-small cell lung cancer (NSCLC) and has been associated with improved median overall survival (OS)...

32 Review of pemetrexed with platinum chemotherapy for locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC) in Northern Ireland

32 Review of pemetrexed with platinum chemotherapy for locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC) in Northern Ireland

34 Pemetrexed and carboplatin (PC) doublet in advanced non squamous non-small cell lung cancer. Real life experience from a cancer unit

34 Pemetrexed and carboplatin (PC) doublet in advanced non squamous non-small cell lung cancer. Real life experience from a cancer unit

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

TPS8122 Background: NSCLC is the leading cause of cancer death worldwide, exceeding breast, colon and prostate cancer combined. Most patients (pts) are diagnosed with advanced/recurrent disease. NSCLC therapies have incrementally improved overall survival (OS), but benefit has reached a plateau (median OS for late stage pts is just 1 yr). Squamous cell carcinoma (SCC) represents one quarter of NSCLC cases and has limited treatment options. Pemetrexed and bevacizumab are not approved in SCC, and molecularly targeted therapies have limited application. Single-agent chemotherapy is standard of care following progression with platinum-based doublet chemotherapy (Pt-doublet), resulting in median OS of approximately 7 months. Immune checkpoint blockade in NSCLC may promote tumor regression by reversing tumor-induced immunosuppression and restoring the antitumor immune response. Programmed death-1 (PD-1), an immune checkpoint receptor that negatively regulates T-cell activation, is upregulated in tumor infiltrating lymphocytes; expression of its ligand PD-L1 has been associated with poor prognosis in NSCLC. Nivolumab, a PD-1 receptor blocking antibody, showed encouraging antitumor activity in SCC pts in a phase 1 study, with objective responses (ORs) in 4 pts (27%) and stable disease ≥24 weeks in 1 pt (7%) (3 mg/kg; n=15) (Gettinger S et al; ESMO 2012 [Abstr 1237PD]). We describe an ongoing open-label phase 3 study to compare the clinical benefit of nivolumab vs docetaxel in advanced/metastatic SCC pts following failure of Pt-doublet. Methods: A total of 264 pts will be randomized 1:1 to nivolumab monotherapy 3 mg/kg IV every 2 weeks or docetaxel 75 mg/m2 every 3 weeks until disease progression or unacceptable toxicity. Pts will be stratified by prior paclitaxel use and geographic region. Tumor response will be assessed using modified RECIST 1.1. The co-primary objectives are OR rate and OS. Secondary objectives include progression free survival, clinical benefit in PD ligand 1 (PD-L1+) and PD-L1– subgroups (archived tissue required for entry), durability of and time to OR, and pt proportion with symptom improvement. Clinical trial information: NCT01642004.

Tailored management of advanced squamous non-small cell lung cancer (NSCLC)

Lung cancer is the leading cause of cancer-related death worldwide, and squamous cell carcinoma is the second most frequent histological subtype. The improvement registered in the last years in the treatment of non-small cell lung cancer is attributable in part to the concept of personalized therapy, and to the possibility to transfer biological discoveries into clinical practice. Major changes have mainly characterized the adenocarcinoma histology, with the detection of the EGFR mutation and the EML4-ALK translocation, targeted by specific tyrosine kinase inhibitors. Despite its interesting oncogenic profile, squamous carcinoma is not the most appropriate example of "druggable disease", as it is characterized by deplorable results, often with a huge toxicity profile and without any benefit in terms of overall survival. At the present time, cytotoxic drugs are still the only treatment options for patients with advanced squamous cell carcinoma. Recent advances in the molecular characterization of squamous carcinoma have identified mutations and alterations, and clinical trials are ongoing to target these changes.

The role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy.

7032 Background: The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR-TKIs and initial chemotherapy in advanced non squamous non-small cell lung cancer (NSCLC). We reviewed EGFR mutation status in patients with non-squamous NSCLC, and then analyzed the association between the EGFR mutations and the outcome of combination chemoradiotherapy in stage III non-squamous NSCLC. Methods: Patients with stage III non-squamous NSCLC who had identified EGFR mutation status were retrospectively analyzed, 87 patients of those were evaluated response to combination chemoradiotherapy and 2 years survival rate, and128 patients of those could be evaluated response to initial chemotherapy. Results: The objective response rate to combination chemoradiotherapy was 84.6% (33/39) in patients with mutation-positive EGFR, significantly higher than 56.3% (27/48) in those with mutation-negative EGFR (P=0.004). By comparing the images of pre- and post-thoracic radiotherapy, the response rate to thoracic radiotherapy with or without concurrent chemotherapy was 79.5% (31/39) in patients with mutation-positive EGFR and 50% (24/48) in those with mutation-negative EGFR. The overall response rate to initial chemotherapy was 34.5% (19/55) in patients with mutation-positive EGFR, as compared 21.9% (16/73) in those with mutation-negative EGFR. Two years survival rate was 53.8% in patients with mutation-positive EGFR and 50% in those with mutation-negative EGFR. There was no difference in overall survival for patients with mutation-positive EGFR compared with those with mutation-negative EGFR. Conclusions: EGFR mutation-positive status can predict better response to combination chemoradiotherapy, but do not associate with overall survival in patients with stage III non-squamous NSCLC.